Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- FDA Accepts NDA for Aricept Transdermal Patch: Eisai, Teikoku Seiyaku
October 4, 2010
- Takara Bio to Obtain Anticancer Agent from M's Science
October 4, 2010
- Japan's Own COI Disclosure System Necessary: Mr Hirai
October 4, 2010
- FDA Advisory Committee Not Recommend Approval for Lorcaserin: Eisai
October 4, 2010
- Kyowa Kirin Begins PIIb Trial for KW-0761 in Japan
October 4, 2010
- 2.4 Mil. Patients Suffer from Lumbar Canal Stenosis in Japan
October 4, 2010
- AnGes MG to Conduct Additional Trial for Collategene
October 4, 2010
- Peretinoin Reduces Risk of HCC Recurrence after Curative Therapy: Kowa
October 4, 2010
- New Anti-Epileptic Drug E Keppra: Otsuka, UCB
October 4, 2010
- NBI to Withdraw Alotec in Japan
October 4, 2010
- Pletaal Reduces Risk of Stroke, Hemorrhage in Japanese CI Patients: Otsuka
October 4, 2010
- Bendamustine Launched in Singapore: SymBio, Eisai
September 27, 2010
- The Pharma Gospel of Praise
Philip Carrigan
Partner, Optia Partners
philip@optiapartners.com
September 27, 2010
- Daiichi Sankyo Wins Appellate Court Litigation against Mylan
September 27, 2010
- Torisel Ensures Good Compliance with IV Infusion Once a Week: Prof. Horie
September 27, 2010
- Re-Pricing Rule to Be Included in Chuikyo Agenda: Mr Yoshida
September 27, 2010
- Actemra to Change Paradigm for Treatment of RA: Chugai
September 27, 2010
- Int'l Harmonization Conference to Be Created on Drug-Device Combination Products
September 27, 2010
- All-Patients Post-Marketing Investigation on Avastin Finished
September 27, 2010
- Korosho to Support Development of First-in-Class Drugs
September 27, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…